134564-82-2

Basic information

• Product Name: Befloxatone
• Synonyms: Befloxatone;(R)-5-(methoxymethyl)-3-(4-((R)-4,4,4-trifluoro-3-hydroxybutoxy)phenyl)oxazolidin-2-one
• CAS NO: 134564-82-2
• Molecular Formula: C₁₅H₁₈F₃NO₅
• Molecular Weight: 349.303
• Mol File: 134564-82-2.mol
• Article Data: 2

Chemical Properties

• Melting Point: 101°
• Boiling Point: 447.3 °C at 760 mmHg
• Flash Point: 224.3 °C
• Appearance: /
• Density: 1.326 g/cm³
• Vapor Pressure: 8.73E-09mmHg at 25°C
• Refractive Index: 1.498
• PKA: 12.13±0.20(Predicted)
• CAS DataBase Reference: Befloxatone(CAS DataBase Reference)
• NIST Chemistry Reference: Befloxatone(134564-82-2)
• EPA Substance Registry System: Befloxatone(134564-82-2)

Safety Data

• Hazardous Substances Data: 134564-82-2(Hazardous Substances Data)

Usage

Description

Befloxatone, also known as befloxatone hydrochloride, is a pharmaceutical compound that functions as a selective and reversible inhibitor of monoamine oxidase A (MAO-A). It is characterized by its ability to modulate the levels of monoamines in the brain, which are neurotransmitters involved in mood regulation. This property makes Befloxatone a promising candidate for the treatment of various mood disorders and mental health conditions.

Uses

Used in Pharmaceutical Industry:
Befloxatone is used as an antidepressant for the treatment of resistant depression. It acts as a third-line agent, providing an alternative treatment option for patients who do not respond well to first and second-line antidepressants. By selectively inhibiting MAO-A, Befloxatone helps to increase the levels of monoamines such as serotonin, norepinephrine, and dopamine in the brain, which can lead to an improvement in mood and a reduction in depressive symptoms.
In addition to its primary use in treating resistant depression, Befloxatone may also have potential applications in other areas of mental health and neuroscience. However, further research and clinical trials would be necessary to explore these possibilities and establish the safety and efficacy of Befloxatone in these contexts.

InChI:InChI=1/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m1/s1

Upstream product

• 135859-37-9 4,4,4-trifluoro-3-hydroxybutyl 4-methylbenzenesulfonate 
• 51388-20-6 4-benzyloxyaniline hydrochloride 
• 73422-62-5 3-(4-hydroxyphenyl)-5-(methoxymethyl)oxazolidin-2-one 
• 693830-78-3 methyl (4-(benzyloxy)phenyl)carbamate 

Relevant articles and documents

The fluorine-containing α, β - production of unsaturated aldehydes

The purpose of the present invention is to provide a fluorine-containing alpha,beta-unsaturated aldehyde, a method for producing same, an optically active fluorine-containing compound using the fluorine-containing alpha,beta-unsaturated aldehyde, and a method for producing same. This method for producing a fluorine-containing alpha,beta-unsaturated aldehyde is a method for producing a fluorine-containing alpha,beta-unsaturated aldehyde represented by formula (1) and comprises: an oxidizing step of oxidizing an alcohol represented by formula (2) in a high-boiling-point solvent, which has a higher boiling point than the corresponding alpha,beta-unsaturated aldehyde, by using an oxidizing agent that is insoluble to the high-boiling-point solvent; and a purifying step of purifying the reaction solution obtained in the oxidizing step by distillation. In formulae (1) and (2), R1 and R2 each independently represent a hydrogen atom or a fluorine atom, and X is 2 or 3.